Targeting Cancer in the Bone with the Hypoxia Activated Pro-Drug EvofosfamideVasilios Liapis(Basil Hetzel Institute)Adelaide Research & Scholarship (AR&S) (University of Adelaide)January 1, 2017Cited by 0SaveCiteExport RISWatch citationsRelated PapersAnticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models|Cancer Medicine|2016|30